Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, 2-Part, Randomized, Double-Blind, Parallel-Group, Single-Dose Study to Compare the Pharmacokinetics, Safety and Immunogenicity of Three Subcutaneous Injection Formulations of Ustekinumab in Healthy Male Subjects

NCT04428814 is registered in ClinicalTrials.gov with Celltrion as lead sponsor.

NCT NCT04428814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04428814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, 2-Part, Randomized, Double-Blind, Parallel-Group, Single-Dose Study to Compare the Pharmacokinetics, Safety and Immunogenicity of Three Subcutaneous Injection Formulations of Ustekinumab in Healthy Male Subjects
Lead sponsor
Celltrion
Phase
Phase 1
Overall status
Completed
Start date
August 3, 2020
Completion date
February 24, 2021
Enrollment
271 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subjects